Paul Howard Howard, PhD

Philadelphia, Pennsylvania, United States
Paul is an accomplished healthcare policy leader with a proven track record of directing large-scale programs and high impact communications to prepare the industry for the future of healthcare technology and value-driven reimbursement. He is dedicated to leveraging policy and government experience to advance the mission of organizations driving innovation to improve patient outcomes and is recognized as an impassioned leader and effective communicator with the ability to cultivate a vision based on shared values.
He is currently Senior Director of Public Policy at Amicus Therapeutics, where he is responsible for ensuring consistent and appropriate implementation of overarching public policy initiatives and messages within the US that help shape the legislative, reimbursement, and regulatory environment for the development and marketing of products for the treatment of rare and genomic disorders.
Previously, he was Senior Advisor to the Commissioner of the U.S. Food and Drug Administration (2017-19) on regulatory policy, strategic innovation initiatives, and promoting competition to efficiently advance public health and safety; while at the agency he also worked as the Chief Strategy Officer for the Information Exchange and Data Transformation (INFORMED) Program, where he consulted directly with key opinion leaders across the U.S. Department of Health and Human Services, academic institutions, FDA subject matter experts, and leading technology firms to build an agile framework for modernizing the agency’s existing tools for assessing safety and efficacy data in the pre- and post-market.
Prior to joining the U.S. FDA, he was a Senior Fellow and Director of Health Policy at the Manhattan Institute, where he wrote on a wide variety of medical-policy issues, including FDA reform, biopharmaceutical innovation, consumer-driven health care, and Medicare and Medicaid modernization.

He is currently a co-chair of the Regulatory Working Group and member of the Executive Committee at the Alliance for Artificial Intelligence in Healthcare; he is also co-Chair of the Regulatory Working Group the EveryLife Foundation.
Speaking In
1:00 PM - 2:00 PM (PDT)
Monday, June 13
Learn how different organizations are approaching using AI/ML, their thoughts on the challenges and…
1:45 PM - 2:45 PM (PDT)
Wednesday, June 15
Drug development remains a field defined by failure, with roughly 90% of products entering clinical…